JP2022535609A5 - - Google Patents

Info

Publication number
JP2022535609A5
JP2022535609A5 JP2021573165A JP2021573165A JP2022535609A5 JP 2022535609 A5 JP2022535609 A5 JP 2022535609A5 JP 2021573165 A JP2021573165 A JP 2021573165A JP 2021573165 A JP2021573165 A JP 2021573165A JP 2022535609 A5 JP2022535609 A5 JP 2022535609A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
adc
alkyl
treatment
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535609A (ja
JP7740994B2 (ja
Filing date
Publication date
Priority claimed from GBGB1908233.8A external-priority patent/GB201908233D0/en
Priority claimed from GBGB1908234.6A external-priority patent/GB201908234D0/en
Application filed filed Critical
Priority claimed from PCT/EP2020/065880 external-priority patent/WO2020249528A1/en
Publication of JP2022535609A publication Critical patent/JP2022535609A/ja
Publication of JP2022535609A5 publication Critical patent/JP2022535609A5/ja
Application granted granted Critical
Publication of JP7740994B2 publication Critical patent/JP7740994B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573165A 2019-06-10 2020-06-08 抗cd19抗体薬物複合体とpi3k阻害剤又は二次薬剤を含む併用治療 Active JP7740994B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1908233.8A GB201908233D0 (en) 2019-06-10 2019-06-10 Combination therapy
GBGB1908234.6A GB201908234D0 (en) 2019-06-10 2019-06-10 Combination therapy
GB1908233.8 2019-06-10
GB1908234.6 2019-06-10
PCT/EP2020/065880 WO2020249528A1 (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent

Publications (3)

Publication Number Publication Date
JP2022535609A JP2022535609A (ja) 2022-08-09
JP2022535609A5 true JP2022535609A5 (cg-RX-API-DMAC7.html) 2023-06-13
JP7740994B2 JP7740994B2 (ja) 2025-09-17

Family

ID=71103360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573165A Active JP7740994B2 (ja) 2019-06-10 2020-06-08 抗cd19抗体薬物複合体とpi3k阻害剤又は二次薬剤を含む併用治療

Country Status (11)

Country Link
US (1) US20220305132A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980079A1 (cg-RX-API-DMAC7.html)
JP (1) JP7740994B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220020332A (cg-RX-API-DMAC7.html)
CN (1) CN114302745A (cg-RX-API-DMAC7.html)
AU (1) AU2020292965B2 (cg-RX-API-DMAC7.html)
CA (1) CA3142645A1 (cg-RX-API-DMAC7.html)
IL (1) IL288716B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021015403A (cg-RX-API-DMAC7.html)
SG (1) SG11202113092WA (cg-RX-API-DMAC7.html)
WO (1) WO2020249528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240197783A1 (en) 2021-04-21 2024-06-20 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
US20260060969A1 (en) * 2022-08-04 2026-03-05 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
EP4585596A4 (en) * 2022-09-09 2025-12-10 Shanghai Yingli Pharm Co Ltd Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof
US12706617B2 (en) 2023-04-27 2026-08-11 Hewlett Packard Enterprise Development Lp Selective filtering to reduce interferences in Wi-Fi communications
US12609718B2 (en) 2023-06-14 2026-04-21 Hewlett Packard Enterprise Development Lp WiFi-7 optimized split band architecture and method of operation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AU2011229862B2 (en) 2010-03-25 2014-07-24 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
PT2906248T (pt) * 2012-10-12 2019-03-04 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
DK2839860T3 (da) * 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
DK2906298T3 (en) * 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) * 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201506399D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201602356D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
GB201617466D0 (en) * 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3612839A1 (en) * 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy
KR102442736B1 (ko) * 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
GB201806022D0 (en) * 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA3107085A1 (en) * 2018-08-31 2020-03-05 Adc Therapeutics Sa Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax
WO2020109251A1 (en) * 2018-11-29 2020-06-04 Adc Therapeutics Sa Dosage regime
CN111410666B (zh) * 2019-01-04 2021-02-19 苏州亚盛药业有限公司 一种制备磺胺类化合物的工艺
CA3245067A1 (en) * 2022-02-28 2023-08-31 Adc Therapeutics Sa DOSAGE REGIMEN

Similar Documents

Publication Publication Date Title
JP7190549B2 (ja) Hdac阻害剤とpd-1阻害剤との組み合わせ療法
JP2019518741A5 (cg-RX-API-DMAC7.html)
JP2022017295A5 (cg-RX-API-DMAC7.html)
JP2019506403A5 (cg-RX-API-DMAC7.html)
CN106470696B (zh) 用于治疗癌症的药物组合
JP2020505433A5 (cg-RX-API-DMAC7.html)
TW200533339A (en) Therapeutic synergy of anti-cancer compounds
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
JP2008530142A5 (cg-RX-API-DMAC7.html)
JP2018524347A5 (cg-RX-API-DMAC7.html)
FI4234581T3 (fi) Terapeuttisia vasta-aineita ja niiden käyttöjä
SI2809657T1 (en) New therapeutic agents
JP2012509889A5 (cg-RX-API-DMAC7.html)
JP2011503063A5 (cg-RX-API-DMAC7.html)
JP2018503610A5 (cg-RX-API-DMAC7.html)
RU2019138222A (ru) Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
JP2021530444A5 (cg-RX-API-DMAC7.html)
WO2025061140A1 (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途
JP2020524670A5 (cg-RX-API-DMAC7.html)
JP2010534682A5 (cg-RX-API-DMAC7.html)
JP2021535110A5 (cg-RX-API-DMAC7.html)
JP2005514371A (ja) 抗t細胞免疫毒素融合タンパク質およびその治療的使用
TW202102216A (zh) 抗腫瘤組合物
JP2021533090A5 (cg-RX-API-DMAC7.html)
JP5683462B2 (ja) オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ